Chartwell Pharmaceuticals
Yali Elkin has a diverse work experience in various industries. Yali served as the CFO and Executive Vice President at multiple companies such as Delfasco, Inc., Chartwell Pharmaceuticals, and Starfire Systems, Inc. Yali has also held executive positions at CardCash.com and Lucerna, LLC, where they served as the Executive Vice President of Finance and Founding Principal, respectively. Additionally, Yali was the Co-founder and CEO of LiveDial, LLC. Yali has experience in financial management, corporate development, and strategic advisory services. Yali has a proven track record of successfully implementing growth strategies and increasing revenues.
Yali Elkin pursued their education with a Bachelor of Arts degree in History from the University of Pennsylvania, which they completed between 1995 and 1997. Later, between 1999 and 2002, they attended the NYU Stern School of Business, where they obtained their Master of Business Administration (MBA) degree with a focus on Finance, Accounting, and Management.
Chartwell Pharmaceuticals
CHARTING A COURSE TO WELLNESS Chartwell Pharmaceuticals is a US-based development, manufacturing and commercial organization located in Congers, New York. Our facility produces prescription pharmaceutical products with a commitment to superior quality, compliance, and customer service. Chartwell Pharmaceuticals has a long history as a preferred manufacturing partner for prescription solid dosage products in tablet, capsule, and powders forms. Recent expansion now adds capabilities for suspensions, enemas and liquids manufacturing - including Unit Dose cups. Our rooms are large, our ceilings are high, and facilities are pristine. Our exceptional hands-on leadership team and technical staff bring decades of pharmaceutical industry experience in manufacturing and analytical services for development, scale-up, transferring, changing, launching, and supplying products. Under our own Chartwell labels, our mission is to provide a consistent, timely and quality product supply to our pharmacy customers and their patients. Our current portfolio stands at over 250 Orange Book listed ANDAs and NDAs, with an aggressive asset development and acquisition program in place. Supported by Chartwell Labs, our Formulations and Analytical team, we are quickly continuing to broaden our line through commercial Chartwell-labeled branding. Chartwell Pharmaceuticals is proud to be manufacturing "Made in the USA" products.